Trump Suspends Some Morocco Fertilizer Tariffs to Ease U.S. Supply Shortage 
Global Financial Firms Shift Asia Expansion Focus to South Korea as China, India Face Caution 
UN Chief Urges Nations to Close $100 Million UNRWA Funding Gap 
UK House Prices Hold Steady in June as Annual Growth Misses Forecasts 
Asian Stocks End Strong Quarter as Dollar Surges, Yen Hits 40-Year Low Ahead of US Jobs Data 
US Stock Futures Steady as Investors Await Payrolls Data and Monitor Iran Tensions 
Central Banks Eye Gold, Reduce Dollar Exposure as AI Adoption Accelerates: OMFIF Survey 
Oil Prices Rise as U.S.-Iran Talks Keep Geopolitical Risks in Focus 
Gold Prices Drop as Fed Rate Outlook and Iran Tensions Weigh on Market 
China Manufacturing PMI Edges Higher in June as Exports and AI Investment Boost Growth 
Gold Price Hits Annual Low as Fed Rate Hike Bets and Sticky Inflation Weigh on Bullion 
Dollar Slips Ahead of Key U.S. Jobs Data as Fed Rate Outlook, ECB, and Iran Talks Shape Forex Markets 
Oil Prices Slip as U.S.-Iran Peace Talks and Strait of Hormuz Risks Keep Markets on Edge 
Greece’s Bad Loan Crisis Continues to Limit Credit Access Despite Economic Recovery 
U.S. Stocks End Q2 Higher as Strong Jobs Data and AI Rally Lift Wall Street 
Wall Street Futures Rise Ahead of JOLTS Data, Nike Earnings, and U.S.-Iran Talks 
Eli Lilly to Introduce Mounjaro Weight-Loss Drug in Hong Kong by Year-End
Global pharmaceutical giant Eli Lilly is gearing up to launch its weight-loss drug, Mounjaro, in Hong Kong by the end of this year. According to a report from Bloomberg News, the company has received approval from Hong Kong's government to sell its tirzepatide injections under the Mounjaro brand.
Mounjaro for Weight Management and Diabetes
Eli Lilly's Mounjaro is designed for both long-term weight management and the treatment of type 2 diabetes. It will be available on the Kwikpen device, which allows for easy self-administration. The company aims to address the growing demand for effective weight-loss treatments while continuing to provide solutions for diabetes management.
Hong Kong Market Entry
Hong Kong marks a strategic entry point for Eli Lilly as it expands its global presence. With the approval of Mounjaro, the company is poised to offer a highly anticipated solution for individuals struggling with obesity and related health issues. The weight-loss sector has seen significant growth in recent years, and Mounjaro is expected to make a notable impact.
